The OBV at the moment is only about 200k shares positive differential after a ~2M differential (pop).
The longs, it reads to me, are yet to be impressed.
So... $29.99 for the product... hmn... however, a more or less 2M user market world wide according to their marketing. That would make it maybe $8M on the low end, or +$4M to revenue on the low side of new expectation, taking maybe $11M/yr to $15M/yr. ( It must be draconian vs. the $300 prescription )
I would have to wait until next earnings (after a reasonable time for more marketing) to see how well that works. What, 3-6mo ?